IP Library Granted Patent US 6,977,044
Granted Patent B1
US 6,977,044 · App. 10/111,989 · Granted Dec 20, 2005

Filter for selectively removing leukocytes

Assignee: Asahi Medical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,977,044
App. No.
10/111,989
Granted
Dec 20, 2005
Kind
B1
Abstract

A filter for selectively removing leukocytes from the human whole blood, characterized in that it comprises a filter base coated with a hydrophilic synthetic polymer having a weight-average molecular weight of 300,000 to 3,000,000 and that the percentage of covering by the polymer is 70% or higher based on the whole surface of the filter base.

Claims (18)

1. A filter for selectively removing leukocytes from human whole blood, comprising a filter substrate having coated thereon a hydrophilic synthetic polymer in a coating ratio of 70% or more with respect to the overall surface of the filter substrate, said polymer containing a nonionic hydrophilic group and a nitrogen-containing basic functional group, and wherein said polymer having a weight average molecular weight of from 300,000 to 3,000,000.

2. The filter according to claim 1 , wherein said hydrophilic synthetic polymer is a vinyl polymer.

3. The filter according to claim 1 , wherein said filter substrate comprises a polymer containing a functional group having a lone electron pair.

4. The filter according to claim 1 , wherein said filter substrate comprises a thermoplastic polymer.

5. The filter according to claim 1 , wherein said filter substrate is a non-woven fabric.

6. The filter according to claim 1 , wherein said filter substrate has been subjected to at least one treatment selected from the group consisting of energy beam irradiation treatment and electric discharge treatment.

7. The filter according to claim 1 , wherein said hydrophilic synthetic polymer has a molecular weight distribution wherein, in a gel permeation chromatogram of said polymer, the content of low molecular weight fractions having molecular weights which are ¼ or less of the peak-top molecular weight is 10% or less in terms of the percentage of an area in the peak which corresponds to said low molecular weight fractions, based on the entire area of the peak.

8. A method for selectively removing leukocytes from human whole blood, comprising:

contacting human whole blood with the filter of claim 1 , thereby causing leukocytes contained in the human whole blood to selectively adhere to said filter while allowing plasma, red cells and platelets contained in the human whole blood to pass through said filter to obtain a leukocyte-removed blood suspension, and

collecting said leukocyte-removed blood suspension.

9. The filter according to claim 2 , wherein said filter substrate comprises a polymer containing a functional group having a lone electron pair.

10. The filter according to claim 2 , wherein said filter substrate comprises a thermoplastic polymer.

11. The filter according to claim 2 , wherein said filter substrate is a non-woven fabric.

12. The filter according to claim 2 , wherein said filter substrate has been subjected to at least one treatment selected from the group consisting of energy beam irradiation treatment and electric discharge treatment.

13. The filter according to claim 2 , wherein said hydrophilic synthetic polymer has a molecular weight distribution wherein, in a gel permeation chromatogram of said polymer, the content of low molecular weight fractions having molecular weights which are ¼ or less of the peak-top molecular weight is 10% or less in terms of the percentage of an area in the peak which corresponds to said low molecular weight fractions, based on the entire area of the peak.

14. A method for selectively removing leukocytes from human whole blood, comprising:

contacting human whole blood with the filter of claim 2 , thereby causing leukocytes contained in the human whole blood to selectively adhere to said filter while allowing plasma, red cells and platelets contained in the human whole blood to pass through said filter to obtain a leukocyte-removed blood suspension, and

collecting said leukocyte-removed blood suspension.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE TO READ ASAHI KASEI MEDICAL CO., LTD. PREVIOUSLY RECORDED ON REEL 021138 FRAME 0451. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE. Recorded Jul 11, 2008
From: ASAHI KASEI KURARAY MEDICAL CO., LTD.
To: ASAHI KASEI MEDICAL CO., LTD.
Reel/Frame 021217/0762 →
CHANGE OF NAME Recorded Jun 24, 2008
From: ASAHI MEDICAL CO., LTD. OR ASAHI KASEI MEDICAL CO. LTD.
To: ASAHI KASEI KURARAY MEDICAL CO., LTD.
Reel/Frame 021138/0422 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2008
From: ASAHI KASEI KURARAY MEDICAL CO., LTD.
To: ASAHI MEDICAL CO., LTD.
Reel/Frame 021138/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2002
From: OISHI, TERUHIKO; MIURA, MORIKAZU; FUKUDA, TATSUYA; MIURA, HIROFUMI
To: ASAHI MEDICAL CO., LTD.
Reel/Frame 012995/0479 →
Priority Claims (3)
JP 11-311474 · Nov 1, 1999 · national
JP 2000-049729 · Feb 25, 2000 · national
JP 2000-099715 · Mar 31, 2000 · national